dicycloverine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
spasmolytics with a papaverine-like action 868 77-19-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dicymine
  • dicycloverine hydrochloride
  • dicycloverine
  • dicyclomine
  • dicycloverin
  • dicyclomine hydrochloride
  • dicyclomine HCl
A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.
  • Molecular weight: 309.49
  • Formula: C19H35NO2
  • CLOGP: 6.14
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 29.54
  • ALOGS: -4.98
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
80 mg O
80 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.30 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 67 %
S (Water solubility) 50 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.755 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.046 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 11.015 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 19.770 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 3.120 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 5.420 % High 1
herg hERG pIC50 5.297 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 48.865 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 74.645 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 1.420 % High 1
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1 35
kinase-selectivity-class AXL,EIF2AK3,GRK2,PDK4,STK33,TTK 6
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.349 High 1
mh-clint Mouse hepatocyte intrinsic clearance 183.231 High 1
mppb Mouse plasma protein binding (% unbound) 1.610 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.472 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 6.700 % High 1
rh-clint Rat hepatocyte intrinsic clearance 310.456 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 5.730 % High 1
rppb Rat plasma protein binding (% unbound) 2.680 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 239.883 uM High 1

Approvals:

DateAgencyCompanyOrphan
May 11, 1950 FDA FOREST LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cholecystitis chronic 93.86 12.68 51 29205 9775 90589416
Synovitis 92.92 12.68 3 29253 329749 90269442
Anxiety 84.12 12.68 255 29001 309517 90289674
Contraindicated product administered 83.37 12.68 5 29251 320134 90279057
Product dose omission issue 79.08 12.68 240 29016 291447 90307744
Maternal exposure during pregnancy 68.68 12.68 16 29240 360047 90239144
Diarrhoea 67.85 12.68 526 28730 938664 89660527
Abdominal pain 65.52 12.68 277 28979 395444 90203747
Glossodynia 64.00 12.68 13 29243 321766 90277425
Systemic lupus erythematosus 61.69 12.68 20 29236 361876 90237315
Helicobacter infection 60.73 12.68 3 29253 226847 90372344
Arthropathy 57.73 12.68 23 29233 366219 90232972
Vulvovaginal burning sensation 57.37 12.68 24 29232 2571 90596620
Biliary dyskinesia 57.34 12.68 24 29232 2575 90596616
Wound 56.71 12.68 14 29242 302966 90296225
General physical health deterioration 56.47 12.68 22 29234 355093 90244098
Rhinalgia 54.70 12.68 23 29233 2495 90596696
Folliculitis 53.76 12.68 3 29253 204350 90394841
Drug intolerance 53.30 12.68 40 29216 447551 90151640
Treatment failure 51.43 12.68 17 29239 303911 90295280
Vulvovaginal pruritus 50.42 12.68 25 29231 3968 90595223
Gallbladder disorder 49.24 12.68 45 29211 19758 90579433
Surgery 47.09 12.68 65 29191 44822 90554369
Hepatic enzyme increased 43.24 12.68 32 29224 360704 90238487
Stress 41.13 12.68 85 29171 81310 90517881
Palpitations 40.31 12.68 116 29140 136612 90462579
Urinary tract infection 40.16 12.68 200 29056 305432 90293759
Paranasal sinus discomfort 40.10 12.68 25 29231 6185 90593006
Abdominal pain lower 39.92 12.68 49 29207 30128 90569063
Impaired healing 39.78 12.68 13 29243 234186 90365005
Diverticulitis 39.48 12.68 60 29196 45127 90554064
Illness 38.40 12.68 83 29173 81886 90517305
Nausea 37.45 12.68 533 28723 1109783 89489408
Joint swelling 36.28 12.68 67 29189 503233 90095958
Constipation 34.39 12.68 180 29076 280215 90318976
Depression 34.18 12.68 189 29067 300412 90298779
Nasal congestion 34.09 12.68 80 29176 83334 90515857
Nasal dryness 32.37 12.68 21 29235 5562 90593629
Rheumatoid arthritis 32.10 12.68 42 29214 362572 90236619
Pre-existing condition improved 31.31 12.68 25 29231 9144 90590047
C-reactive protein increased 30.92 12.68 10 29246 181379 90417812
Sleep disorder due to general medical condition, insomnia type 30.69 12.68 3 29253 128691 90470500
Headache 30.57 12.68 418 28838 862328 89736863
Ill-defined disorder 30.12 12.68 11 29245 184880 90414311
Clostridium difficile infection 30.08 12.68 47 29209 36198 90562993
Nasal discomfort 30.06 12.68 20 29236 5528 90593663
Increased appetite 29.77 12.68 27 29229 11738 90587453
Impaired gastric emptying 29.70 12.68 28 29228 12781 90586410
Abdominal distension 29.46 12.68 101 29155 130500 90468691
Therapeutic product effect decreased 29.10 12.68 28 29228 277543 90321648
Emotional distress 28.30 12.68 46 29210 36616 90562575
Flatulence 28.08 12.68 49 29207 41318 90557873
Injection site extravasation 27.46 12.68 23 29233 8996 90590195
Small intestinal obstruction 27.32 12.68 34 29222 21200 90577991
Fungal infection 26.98 12.68 49 29207 42612 90556579
Fall 26.78 12.68 255 29001 481555 90117636
Completed suicide 25.87 12.68 104 29152 144954 90454237
Upper-airway cough syndrome 25.78 12.68 28 29228 15107 90584084
Poor peripheral circulation 25.48 12.68 16 29240 4009 90595182
Alopecia 25.27 12.68 79 29177 494992 90104199
Exposure during pregnancy 25.04 12.68 24 29232 238386 90360805
Infusion related reaction 24.60 12.68 62 29194 416718 90182473
Wound infection 24.05 12.68 3 29253 106399 90492792
Abdominal pain upper 23.66 12.68 186 29070 332488 90266703
Oropharyngeal pain 23.33 12.68 86 29170 115101 90484090
Blister 23.11 12.68 29 29227 254969 90344222
Type 2 diabetes mellitus 23.10 12.68 19 29237 203225 90395966
Weight decreased 23.08 12.68 205 29051 379705 90219486
Back pain 22.92 12.68 178 29078 316997 90282194
Product administration interrupted 22.85 12.68 24 29232 12468 90586723
Intestinal obstruction 22.67 12.68 42 29214 37089 90562102
Chronic kidney disease 22.57 12.68 50 29206 50141 90549050
Lower respiratory tract infection 22.21 12.68 29 29227 250630 90348561
Therapy partial responder 21.75 12.68 31 29225 22012 90577179
Scleritis 21.73 12.68 16 29240 5192 90593999
Cholelithiasis 21.06 12.68 50 29206 52456 90546735
Feeling abnormal 20.92 12.68 108 29148 167127 90432064
Vitamin D deficiency 20.83 12.68 27 29229 17529 90581662
Hypercholesterolaemia 20.20 12.68 4 29252 100888 90498303
Dehydration 19.94 12.68 119 29137 194328 90404863
Thrombocytopenia 19.69 12.68 23 29233 208702 90390489
Hip fracture 19.67 12.68 37 29219 33040 90566151
Aphthous ulcer 19.60 12.68 26 29230 17261 90581930
Colitis ulcerative 19.59 12.68 53 29203 60213 90538978
Vascular access site pain 19.47 12.68 7 29249 499 90598692
Joint range of motion decreased 19.04 12.68 10 29246 135633 90463558
Psoriatic arthropathy 18.64 12.68 28 29228 228307 90370884
Discomfort 18.45 12.68 38 29218 274297 90324894
Mobility decreased 18.37 12.68 33 29223 250701 90348490
Drug ineffective 18.31 12.68 326 28930 1383972 89215219
Bursitis 18.05 12.68 10 29246 131644 90467547
Haematochezia 17.91 12.68 57 29199 70856 90528335
Infusion site erythema 17.76 12.68 22 29234 13648 90585543
COVID-19 17.74 12.68 104 29152 168739 90430452
Therapeutic response unexpected 17.64 12.68 28 29228 21852 90577339
Colitis 17.47 12.68 56 29200 69886 90529305
Confusional state 17.40 12.68 65 29191 386140 90213051
Drug-induced liver injury 17.22 12.68 4 29252 90314 90508877
Lung disorder 17.04 12.68 14 29242 149869 90449322
Therapeutic reaction time decreased 17.01 12.68 12 29244 3646 90595545
Injection site pain 16.98 12.68 105 29151 173594 90425597
Essential hypertension 16.98 12.68 15 29241 6300 90592891
Influenza 16.77 12.68 89 29167 139175 90460016
Dizziness 16.70 12.68 275 28981 589009 90010182
Suicidal ideation 16.54 12.68 57 29199 73798 90525393
Gallbladder injury 15.97 12.68 8 29248 1298 90597893
Bronchitis 15.94 12.68 94 29162 152833 90446358
Fatigue 15.71 12.68 485 28771 1153538 89445653
Hospitalisation 15.52 12.68 82 29174 128018 90471173
Sinus congestion 15.47 12.68 30 29226 27394 90571797
Muscle spasms 15.32 12.68 136 29120 251747 90347444
Intestinal mucosal hypertrophy 15.09 12.68 5 29251 279 90598912
Vision blurred 15.04 12.68 73 29183 110220 90488971
Epilepsy 14.98 12.68 4 29252 82202 90516989
Dermatitis atopic 14.89 12.68 27 29229 23445 90575746
Tonsillitis fungal 14.89 12.68 3 29253 21 90599170
Insurance issue 14.83 12.68 18 29238 10940 90588251
Intentional dose omission 14.67 12.68 23 29233 17760 90581431
Oral herpes 14.62 12.68 33 29223 33491 90565700
Presbyopia 14.42 12.68 6 29250 634 90598557
Migraine 14.38 12.68 108 29148 190284 90408907
Nervousness 14.28 12.68 33 29223 34023 90565168
Pain 14.15 12.68 421 28835 995920 89603271
Skin laceration 14.11 12.68 28 29228 26007 90573184
Hypothermia 14.05 12.68 21 29235 15554 90583637
Hysterectomy 14.03 12.68 18 29238 11566 90587625
Gait inability 13.96 12.68 16 29240 146440 90452751
Cough 13.92 12.68 181 29075 368781 90230410
Autoimmune disorder 13.49 12.68 4 29252 76740 90522451
Auditory disorder 13.49 12.68 7 29249 1223 90597968
Hip arthroplasty 13.34 12.68 4 29252 76204 90522987
Pancreatitis acute 13.33 12.68 31 29225 32084 90567107
Somnambulism 13.28 12.68 13 29243 6215 90592976
Allergic reaction to excipient 13.22 12.68 6 29250 782 90598409
Mydriasis 13.20 12.68 20 29236 14992 90584199
Restless legs syndrome 13.19 12.68 25 29231 22445 90576746
Neutropenia 12.83 12.68 34 29222 224870 90374321
Pharyngitis streptococcal 12.69 12.68 18 29238 12724 90586467

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abdominal pain 39.98 16.00 88 6291 190383 42424573
Irritable bowel syndrome 28.64 16.00 14 6365 4667 42610289
Diarrhoea 27.06 16.00 138 6241 460711 42154245
Hypogonadism 26.86 16.00 11 6368 2423 42612533
Axillary vein thrombosis 23.17 16.00 6 6373 307 42614649
Alkalosis hypochloraemic 22.76 16.00 6 6373 329 42614627
Eosinophilic oesophagitis 22.41 16.00 7 6372 705 42614251
Abdominal pain upper 21.79 16.00 42 6337 82567 42532389
Aplastic anaemia 20.36 16.00 16 6363 12368 42602588
Nausea 19.97 16.00 114 6265 396685 42218271
Weight decreased 19.64 16.00 72 6307 207876 42407080
Product dose omission issue 18.59 16.00 58 6321 154307 42460649
Fatigue 16.82 16.00 117 6262 435524 42179432
Colitis ulcerative 16.54 16.00 20 6359 26155 42588801
Headache 16.36 16.00 75 6304 239294 42375662
Apathy 16.33 16.00 12 6367 8394 42606562
Rectourethral fistula 16.33 16.00 3 6376 29 42614927

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cholecystitis chronic 86.58 13.07 44 27787 9456 110552012
Abdominal pain 80.06 13.07 297 27534 512692 110048776
Product dose omission issue 73.32 13.07 212 27619 321570 110239898
Vulvovaginal burning sensation 68.47 13.07 24 27807 2045 110559423
Diarrhoea 67.26 13.07 503 27328 1139002 109422466
Anxiety 66.14 13.07 214 27617 344864 110216604
Synovitis 56.65 13.07 3 27828 274089 110287379
Vulvovaginal pruritus 54.02 13.07 23 27808 3308 110558160
Biliary dyskinesia 53.96 13.07 21 27810 2400 110559068
Rhinalgia 53.54 13.07 24 27807 3905 110557563
General physical health deterioration 48.79 13.07 23 27808 425272 110136196
Gallbladder disorder 48.26 13.07 41 27790 20988 110540480
Paranasal sinus discomfort 45.16 13.07 25 27806 6380 110555088
Diverticulitis 44.65 13.07 61 27770 53461 110508007
Pericarditis 43.46 13.07 3 27828 219111 110342357
Headache 41.36 13.07 370 27461 882007 109679461
Abdominal pain lower 39.76 13.07 48 27783 37235 110524233
Urinary tract infection 38.18 13.07 173 27658 326109 110235359
Nausea 38.11 13.07 476 27355 1235214 109326254
Pain 36.19 13.07 383 27448 954572 109606896
Drug intolerance 35.60 13.07 30 27801 406482 110154986
Clostridium difficile infection 35.56 13.07 54 27777 52075 110509393
Nasal dryness 34.12 13.07 20 27811 5686 110555782
Abdominal pain upper 33.58 13.07 175 27656 348936 110212532
Nasal discomfort 32.64 13.07 20 27811 6161 110555307
Completed suicide 32.55 13.07 134 27697 242247 110319221
Injection site extravasation 32.29 13.07 24 27807 10145 110551323
Maternal exposure during pregnancy 32.08 13.07 12 27819 254871 110306597
Small intestinal obstruction 31.97 13.07 40 27791 32173 110529295
Nasal congestion 31.87 13.07 74 27757 98208 110463260
Palpitations 31.59 13.07 100 27731 159112 110402356
Surgery 31.38 13.07 45 27786 41238 110520230
Impaired gastric emptying 30.70 13.07 26 27805 13249 110548219
Treatment failure 28.82 13.07 17 27814 277217 110284251
Folliculitis 28.79 13.07 4 27827 167649 110393819
Upper-airway cough syndrome 28.62 13.07 27 27804 15830 110545638
Fatigue 28.00 13.07 445 27386 1215513 109345955
Increased appetite 27.99 13.07 26 27805 14951 110546517
Wound 27.93 13.07 12 27819 234425 110327043
Systemic lupus erythematosus 27.29 13.07 15 27816 254323 110307145
Oropharyngeal pain 26.87 13.07 85 27746 135191 110426277
Stress 26.48 13.07 72 27759 105276 110456192
Emotional distress 25.82 13.07 43 27788 44804 110516664
Multiple organ dysfunction syndrome 25.18 13.07 4 27827 151706 110409762
Colitis ulcerative 24.81 13.07 58 27773 77305 110484163
Illness 24.62 13.07 60 27771 82111 110479357
Constipation 24.48 13.07 164 27667 357622 110203846
Intestinal obstruction 24.17 13.07 46 27785 53181 110508287
Back pain 24.16 13.07 168 27663 370828 110190640
Glossodynia 23.95 13.07 13 27818 221991 110339477
Neutropenia 23.68 13.07 36 27795 374584 110186884
Flatulence 23.59 13.07 45 27786 52104 110509364
Hypogonadism 23.47 13.07 11 27820 1983 110559485
C-reactive protein increased 23.16 13.07 13 27818 217906 110343562
Arthropathy 23.04 13.07 23 27808 287499 110273969
Abdominal distension 22.87 13.07 96 27735 175007 110386461
Aphthous ulcer 22.19 13.07 27 27804 21109 110540359
Hepatic enzyme increased 22.10 13.07 29 27802 320863 110240605
Hip fracture 22.00 13.07 35 27796 35116 110526352
Pain in extremity 20.59 13.07 200 27631 486918 110074550
Feeling abnormal 20.50 13.07 95 27736 180616 110380852
Vision blurred 20.29 13.07 75 27756 128947 110432521
Chest pain 20.29 13.07 163 27668 376212 110185256
Vascular access site pain 20.06 13.07 7 27824 588 110560880
Rheumatoid arthritis 19.70 13.07 28 27803 299585 110261883
Depression 19.66 13.07 142 27689 317193 110244275
Dermatitis atopic 19.64 13.07 28 27803 25513 110535955
Colitis 19.14 13.07 63 27768 102260 110459208
Injection site pain 19.07 13.07 92 27739 177830 110383638
Fall 18.72 13.07 233 27598 603249 109958219
Presbyopia 18.58 13.07 7 27824 732 110560736
Fungal infection 18.42 13.07 40 27791 50766 110510702
Device issue 18.41 13.07 32 27799 34503 110526965
Bronchitis 18.14 13.07 83 27748 156949 110404519
Pancreatitis acute 18.04 13.07 44 27787 60230 110501238
Thrombocytopenia 18.02 13.07 38 27793 348847 110212621
Weight decreased 17.78 13.07 188 27643 467869 110093599
Pre-existing condition improved 17.65 13.07 14 27817 6512 110554956
Oral herpes 17.40 13.07 32 27799 36048 110525420
Sleep disorder due to general medical condition, insomnia type 17.05 13.07 3 27828 105640 110455828
Crying 16.70 13.07 26 27805 25602 110535866
Therapy interrupted 16.68 13.07 38 27793 49784 110511684
Impaired healing 16.62 13.07 15 27816 196702 110364766
Cholelithiasis 16.59 13.07 44 27787 63378 110498090
Dizziness 16.55 13.07 257 27574 697936 109863532
Neck pain 16.46 13.07 68 27763 123062 110438406
Skin laceration 16.36 13.07 30 27801 33723 110527745
Alkalosis hypochloraemic 16.24 13.07 6 27825 595 110560873
Parotitis 16.13 13.07 10 27821 3143 110558325
Lung disorder 16.10 13.07 13 27818 180034 110381434
Hyperkalaemia 16.09 13.07 7 27824 135789 110425679
Ill-defined disorder 15.76 13.07 10 27821 156843 110404625
Proctalgia 15.72 13.07 18 27813 13204 110548264
Tonsillitis fungal 15.63 13.07 3 27828 21 110561447
Haematochezia 15.60 13.07 64 27767 115460 110446008
Essential hypertension 15.40 13.07 14 27817 7833 110553635
Abdominal hernia 15.36 13.07 13 27818 6616 110554852
Interstitial lung disease 15.26 13.07 8 27823 139326 110422142
Mydriasis 15.17 13.07 23 27808 22134 110539334
Cardiac failure 15.04 13.07 15 27816 187611 110373857
Joint swelling 14.97 13.07 59 27772 442786 110118682
Gallbladder injury 14.83 13.07 7 27824 1281 110560187
Obesity 14.83 13.07 5 27826 113346 110448122
Axillary vein thrombosis 14.82 13.07 6 27825 760 110560708
Eosinophilic oesophagitis 14.71 13.07 7 27824 1305 110560163
Sinus congestion 14.67 13.07 27 27804 30432 110531036
Allergic reaction to excipient 14.58 13.07 6 27825 793 110560675
Drug-induced liver injury 14.53 13.07 6 27825 120061 110441407
Type 2 diabetes mellitus 14.40 13.07 14 27817 177218 110384250
Chronic sinusitis 14.37 13.07 24 27807 25060 110536408
Gastric disorder 14.13 13.07 28 27803 33329 110528139
Therapeutic response shortened 13.97 13.07 26 27805 29557 110531911
Dehydration 13.95 13.07 119 27712 279392 110282076
Pain in jaw 13.89 13.07 36 27795 51141 110510327
Discharge 13.85 13.07 8 27823 2214 110559254
Intestinal mucosal hypertrophy 13.82 13.07 5 27826 467 110561001
Migraine 13.78 13.07 82 27749 171570 110389898
Confusional state 13.68 13.07 66 27765 468614 110092854
Muscle spasms 13.66 13.07 118 27713 278039 110283429
Hepatitis 13.60 13.07 3 27828 90051 110471417
Insurance issue 13.56 13.07 15 27816 10597 110550871
Cough 13.35 13.07 176 27655 461465 110100003
Psoriatic arthropathy 13.32 13.07 18 27813 196743 110364725
Therapeutic product effect decreased 13.13 13.07 26 27805 244290 110317178

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A03AA07 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Synthetic anticholinergics, esters with tertiary amino group
FDA MoA N0000175370 Cholinergic Antagonists
FDA EPC N0000175574 Anticholinergic
MeSH PA D010276 Parasympatholytics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
CHEBI has role CHEBI:48876 muscarinic antagonist
CHEBI has role CHEBI:50370 parasympatholytic
CHEBI has role CHEBI:53784 antispasmodic drug

Related Drugs by ATC class:

A03AA Synthetic anticholinergics, esters with tertiary amino group 8 drugs
camylofindifemerinedihexyverinemebeverineoxyphencycliminepiperidolaterociverinetrimebutine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Irritable bowel syndrome indication 10743008 DOID:9778
Calculus in biliary tract off-label use 266474003
Brain damage contraindication 2470005
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Hepatic encephalopathy contraindication 13920009 DOID:13413
Severe chronic ulcerative colitis contraindication 14311001
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Poisoning by phenobarbital contraindication 64921004
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Gastrointestinal obstruction contraindication 126765001
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Benign prostatic hyperplasia contraindication 266569009
Dyspnea contraindication 267036007
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Fever greater than 100.4 Fahrenheit contraindication 426000000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.41 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 9.03 DRUG MATRIX CHEMBL
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Ki 9.08 DRUG MATRIX CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 7.16 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.08 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.61 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.85 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.39 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.80 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 6.60 IUPHAR
Muscarinic acetylcholine receptor M4 GPCR Ki 9.39 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 8.77 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 8.69 DRUG MATRIX
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.55 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 4.77 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor IC50 6.33 DRUG MATRIX
SMR1-alpha2 Unclassified Ki 6.54 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 7.33 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 8.61 CHEMBL

External reference:

IDSource
4017870 VUID
N0000179550 NUI
D00717 KEGG_DRUG
67-92-5 SECONDARY_CAS_RN
152021 RXNORM
4017870 VANDF
4019716 VANDF
C0012125 UMLSCUI
CHEBI:4514 CHEBI
CHEMBL1123 ChEMBL_ID
CHEMBL1200479 ChEMBL_ID
DB00804 DRUGBANK_ID
3042 PUBCHEM_CID
158 MMSL
4587 MMSL
d00999 MMSL
001758 NDDF
004711 NDDF
372732007 SNOMEDCT_US
41493007 SNOMEDCT_US
71043005 SNOMEDCT_US
D004025 MESH_DESCRIPTOR_UI
355 IUPHAR_LIGAND_ID
619 INN_ID
4KV4X8IF6V UNII
4KV4X8IF6V INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0622 SOLUTION 10 mg ORAL ANDA 24 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0748 CAPSULE 10 mg ORAL ANDA 25 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 0143-1227 TABLET 20 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-7384 CAPSULE 10 mg ORAL ANDA 26 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-1980 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 24 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-0586 CAPSULE 10 mg ORAL ANDA 25 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1282 TABLET 20 mg ORAL ANDA 25 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0794 CAPSULE 10 mg ORAL ANDA 25 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0795 TABLET 20 mg ORAL ANDA 25 sections
dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-1161 SOLUTION 10 mg ORAL ANDA 25 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8483 CAPSULE 10 mg ORAL ANDA 25 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8622 TABLET 20 mg ORAL ANDA 28 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-6173 INJECTION 10 mg INTRAMUSCULAR ANDA 25 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6052 TABLET 20 mg ORAL ANDA 30 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6052 TABLET 20 mg ORAL ANDA 30 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6053 CAPSULE 10 mg ORAL ANDA 30 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6053 CAPSULE 10 mg ORAL ANDA 30 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6987 CAPSULE 10 mg ORAL ANDA 25 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6988 TABLET 20 mg ORAL ANDA 25 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-520 CAPSULE 10 mg ORAL ANDA 25 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-560 TABLET 20 mg ORAL ANDA 26 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 10544-597 TABLET 20 mg ORAL ANDA 20 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16571-259 TABLET 20 mg ORAL ANDA 20 sections
DICYCLOMINE HYDROCHLORIDE Human Prescription Drug Label 1 16571-260 CAPSULE 10 mg ORAL ANDA 25 sections
dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16590-077 CAPSULE 10 mg ORAL ANDA 11 sections
DICYCLOMINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-324 TABLET 20 mg ORAL ANDA 8 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0623 SOLUTION 10 mg ORAL ANDA 24 sections
dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-1161 SOLUTION 10 mg ORAL ANDA 20 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-2261 SOLUTION 10 mg ORAL ANDA 27 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 21695-218 CAPSULE 10 mg ORAL ANDA 22 sections